The Comparison of Conventional and Novel Fixed Dose Combination of Rifampicin and Isoniazid to Improve Bioavailability of Rifampicin for Treatment of Tuberculosis

Sanjeev Sinha^1*, Raghunandan P¹, Rashmita Pradhan¹, Shishoo CJ², Manish Nivsarkar², Padh H², Samantaray JC³, Kamal Kishore⁴ and Pandey RM⁵

¹Department of Medicine, All India Institute of Medical Sciences, New Delhi, India

²National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad and B.V.Patel Pharmaceutical Education and Research Development (PERD) Centre, Thaltej, Ahmedabad, India

³Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India

⁴Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India

⁵Department of Biostatistics, All India Institute of Medical Sciences, New Delhi, India

^*Corresponding Author: Sanjeev Sinha, Additional Professor, Department of Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India, Tel: 91-11- 26594440, Fax: 91-11-26588866 Email: